Business Practice

The burden on clinical trials designers and healthcare professionals can only be eased by fixing a broken process: trial feasibility.

Counterfeit deterrents are not yet available in some regions. We speak with Advanco CEO Alf Goebel to find out why.

Cardinal Health’s Fran Gregory looks at innovative payment models for cell and gene therapies.

Sitting Down With Christian Baber of the Pistoia Alliance

Cardinal Health’s Fran Gregory talks about the high costs of cell and gene therapies, and what this means for payers.

The US Inflation Reduction Act continues to generate controversy as drugmakers make counteroffers.

Ali Pashazadeh from Treehill Partners offers his advice for navigating the turbulent period and keeping on track for commercial success.

From renewable energy to bicycle schemes and more; here are just a few examples of how a pharma business can be more sustainable.

Experts from the Access to Medicine Foundation discuss how to reduce the risk of antimicrobial resistance (AMR) in antibiotic manufacturing.

A deep dive into the dangers of fentanyl entering the US supply chain – and the importance of the Drug Supply Chain Security Act